博拓生物实控人于秀萍14天减持448万股 套现1.75亿元

Group 1 - The actual controller of Botao Bio, Yu Xiuping, has completed a share reduction plan, selling a total of 4,479,900 shares, which accounts for 3.00% of the company's total share capital, with a total amount of 175,077,100.70 yuan [1] - Prior to the share reduction, Yu Xiuping held 24,953,600 shares, representing 16.71% of the total shares [1] - The share reduction took place between November 19, 2025, and December 2, 2025, at prices ranging from 38.55 yuan to 41.77 yuan per share [1] Group 2 - Botao Bio's initial public offering raised a total of 921 million yuan, with a net amount of 829 million yuan, which is 62.08 million yuan less than originally planned [2] - The company initially aimed to raise 891 million yuan for various projects, including the expansion of medical device production capacity and the establishment of a research and development center [2] - The total issuance costs for the public offering amounted to 91.96 million yuan, excluding VAT, with underwriting fees of 65.19 million yuan [3]